Lung cancer risk in germline p53 mutation carriers: Association between an inherited cancer predisposition, cigarette smoking, and cancer risk

Human Genetics

Volumn 113, Issue 3, 2003, Pages 238-243

  Hwang, Shih Jen ^a   Cheng, Li Shu Chung ^b   Lozano, Guillermina ^a   Amos, Christopher I ^a   Gu, Xiangjun ^a   Strong, Louise C ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b City of Hope Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; BIRTH; CANCER INCIDENCE; CANCER RISK; CHILDHOOD CANCER; CIGARETTE SMOKING; COHORT ANALYSIS; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; FAMILY; FEMALE; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HETEROZYGOTE DETECTION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN EXPERIMENT; INHERITANCE; KAPLAN MEIER METHOD; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE; SEX; SOFT TISSUE SARCOMA; STATISTICAL ANALYSIS; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SMOKING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0042566080     PISSN: 03406717     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00439-003-0968-7     Document Type: Article

References (30)

1. Alberg AJ, Samet JM (2003) Epidemiology of lung cancer. Chest 123:21S-49S
2. Carbone D (1992) Smoking and cancer. Am J Med 93:13S-17S
3. Data Analysis Products Division (2000) S-PLUS 2000, User's guide; www.stats.ox.ac.uk
4. Doll R (1998) Uncovering the effects of smoking: Historical perspective. Stat Methods Med Res 7:87-117
5. Evans SC, Mims B, McMasters KM, Foster CJ, DeAndrade M, Amos CI, Strong LC, Lozano G (1998) Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family. Hum Genet 102:681-686
6. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron L, Benhattar J (1995) A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 92:3963-3967
7. Hwang SJ, Lozano G, Amos CI, Strong LC (2003) Germline p53 mutations in a cohort with childhood sarcoma: Sex differences in cancer risk. Am J Hum Genet 72:975-983
8. Kleihues P, Schauble B, Zur HA, Esteve J, Ohgaki H (1997) Tumors associated with p53 germline mutations: A synopsis of 91 families. Am J Pathol 150:1-13
9. Kleinerman RA, Tarone RE, Abramson DH, Seddon JM, Li FP, Tucker MA (2000) Hereditary retinoblastoma and risk of lung cancer. J Natl Cancer Inst 92:2037-2039
10. Kondo K, Tsuzuki H, Sasa M, Sumitomo M, Uyama T, Monden Y (1996) A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. J Surg Oncol 61:20-26
11. Koop CE, Luoto J (1982) The health consequences of smoking: Cancer. Overview of a report of the Surgeon General. Public Health Rep 97:318-324
12. Kure EH, Ryberg D, Hewer A, Phillips DH, Skaug V, Baera R, Haugen A (1996) p53 mutations in lung tumours: Relationship to gender and lung DNA adduct levels. Carcinogenesis 17:2201-2205
13. Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A (1989) High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 9:3982-3991
14. Lipsitz SR, Parzen M (1996) A jackknife estimator of variance for Cox regression for correlated survival data. Biometrics 52:291-298
15. Lustbader ED, Williams WR, Bondy ML, Strom S, Strong LC (1992) Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients. Am J Hum Genet 51:344-356
16. Lynch HT GH (1979) Childhood cancer and the SBLA syndrome. Med Hypotheses 5:15-22
17. Lynch HT, Radford B, Lynch JF (1990) SBLA syndrome revisited. Oncology 47:75-79
18. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238
19. Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP (2001) Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 10:83-87
20. Ooi WL, Elston RC, Chen VW, Bailey-Wilson JE, Rothschild H (1986) Increased familial risk for lung cancer. J Natl Cancer Inst 76:217-222
21. SAS Institute (1994) SAS User's Guide: Statistics. SAS Institute, Cary, NC
22. Schwartz AG, Rothrock M, Yang P, Swanson GM (1999) Increased cancer risk among relatives of nonsmoking lung cancer cases. Genet Epidemiol 17:1-15
23. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH (1990) Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348:747-749
24. Strong LC, Stine M, Norsted TL (1987) Cancer in survivors of childhood soft tissue sarcoma and their relatives. J Natl Cancer Inst 79:1213-1220
25. Strong LC, Williams WR, Tainsky MA (1992) The Li-Fraumeni syndrome: From clinical epidemiology to molecular genetics. Am J Epidemiol 135:190-199
26. Suzuki H, Takahashi T, Kuroishi T, Suyama M, Ariyoshi Y, Takahashi T, Ueda R (1992) p53 mutations in non-small cell lung cancer in Japan: Association between mutations and smoking. Cancer Res 52:734-736
27. Varley JM, McGown G, Thorncroft M, Santibanez-Koref MF, Kelsey AM, Tricker KJ, Evans DG, Birch JM (1997) Germ-line mutations of TP53 in Li-Fraumeni families: An extended study of 39 families. Cancer Res 57:3245-3252
28. Wang SS, Samet JM (1997) Tobacco smoking and cancer: The promise of molecular epidemiology. Salud Publica Mex 39:331-345
29. Zang EA, Wynder EL (1992) Cumulative tar exposure. A new index for estimating lung cancer risk among cigarette smokers. Cancer 70:69-76
30. Zhang Z, Liu Q, Lantry LE, Wang Y, Kelloff GJ, Anderson MW, Wiseman RW, Lubet RA, You M (2000) A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents taxol or adriamycin. Cancer Res 60;901-907